Paper Details

  1. Home
  2. Paper Details

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

Author: AsmuthD, BakareN, BlickG, FarthingC, FoliA, FrankI, GreigerP, GroffA, HermanD, LisziewiczJ, LoriFranco, LovaL, NorrisD, PetersonD, PollardR B, RashbaumB, SchraderS, ShalitP, TennenbergA, WhitmanL

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study optimized hydroxyurea dosage for HIV-infected patients, minimizing toxicity while maximizing antiviral efficacy. The optimal dose of 600 mg daily was associated with fewer adverse events and better antiviral efficacy compared to higher doses.
Paper Details　
Original Abstract of the Article :
The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/aid.2005.21.263

データ提供：米国国立医学図書館（NLM）

Optimizing Hydroxyurea Dosage for HIV Treatment

This research delves into the world of HIV treatment, focusing on the optimization of hydroxyurea dosage in combination with didanosine. The authors conducted a randomized, open-label study to determine the optimal dose of hydroxyurea that would minimize toxicity while maximizing antiviral efficacy. This research is important because it aims to improve the effectiveness and tolerability of a widely used HIV treatment regimen.

Lowering Hydroxyurea Dosage: A Key to Improved Efficacy

The study found that a lower dose of hydroxyurea (600 mg daily) was better tolerated and more potent in reducing HIV-1 RNA levels compared to higher doses. This discovery highlights the importance of individualized dosing for optimal treatment outcomes. The researchers also observed that the lower dose was associated with higher CD4+ cell counts and lower CD8+ cell counts, indicating a positive impact on immune function.

Balancing Treatment Efficacy and Safety

This research underscores the importance of striking a balance between treatment efficacy and safety. It emphasizes the need for careful monitoring and adjusting medication dosages to optimize patient outcomes. It also highlights the importance of ongoing research to develop more effective and safer treatments for HIV-infected patients.

Dr. Camel's Conclusion

This study emphasizes the importance of optimizing hydroxyurea dosage for effective HIV treatment. The findings suggest that a lower dose can significantly improve tolerability and antiviral efficacy, potentially leading to better patient outcomes. This research serves as a reminder to carefully consider individual patient needs and optimize treatment regimens for optimal results.

Date :
  1. Date Completed 2005-09-30
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15943568

DOI: Digital Object Identifier

10.1089/aid.2005.21.263

Related Literature

Article Analysis
・Side Effects of didanosine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.